Anthony Wong

Anthony Wong

Anthony C. Wong, M.D., Ph.D.

Assistant Professor
Department of Radiation Oncology

University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
Box 1708,1600 Divisadero St, H1031
San Francisco, CA 94115
Phone: 415 514-2070
Fax: 415 476-7370

Make A Gift Button


Professional Focus

Dr. Anthony Wong specializes in the treatment of thoracic and genitourinary malignancies. His research focuses on innovative applications of stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS). He has a particular interest in treating lung cancer, prostate cancer and oligometastatic disease with linear accelerator-based and CyberKnife radiosurgery. He is the author of a currently accruing randomized clinical trial refining linear accelerator-based radiosurgery techniques, and his work has contributed to a growing body of literature defining the appropriate role of ablative local therapies in patients with oligometastases.


2000-2004 Yale University BS Molecular Biophysics and Biochemistry
2005-2012 Albert Einstein College of Medicine MD, PhD Medicine, Biomedical Sciences
2012-2013 Memorial Sloan-Kettering Cancer Center Internship Transitional Year
2013-2017 University of Chicago Resident Radiation Oncology

Professional Experience

2017- Present University of California, San Francisco Assistant Professor Radiation Oncology

Awards & Honors

2012 Alpha Omega Alpha Honor Medical Society, Kappa New York Chapter
2015 American College of Radiation Oncology Resident Seed Grant
2015 Best of ASTRO abstract selection


Recent Significant Publications :

Das LC, Golden DW, Perevalova E, Wong AC, De Nardo K, Stepaniak C, Joyce DS, McCabe BP, Hasan Y, Chmura SJ, McCall A. A feasibility study of 2-mm bolus for postmastectomy radiation therapy. Pract Radiat Oncol. 2017;7(3):161-6. doi: 10.1016/j.prro.2016.10.015. PubMed PMID: 28089526.

Wong AC, Watson S, Pitroda S, Son CH, Das LC, Stack ME, Uppal, A, Oshima G, Khodarev NN, Salama JK, Weichselbaum RR, Chmura SJ. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer 2016;122(14):2242-2250. PMID: 27206146.

Ranoa D, Parekh A, Pitroda S, Huang X, Darga T, Wong AC, Huang L, Andrade J, Staley J, Satoh T, Akira S, Weichselbaum RR, Khodarev NN. Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs. Oncotarget 2016; 7(18):26496-26515. PMID: 27034163.

Wong AC, Stock S, Schrag D, Kahn KL, Salz T, Charlton ME, Rogers SO, Goodman, KA, Keating NL. Physicians' beliefs about the benefits and risks of adjuvant therapies for stage II and stage III colorectal cancer. J. Oncol. Pract. 2014;10(5):e360-7. PMID: 24986112.